Gold: Like Treasury bonds, gold saw solid buying on Monday as investors continued to add to safe-haven positions. The bullion finished Monday's trading at $5,227, up 2.38%. Worries over the Middle East, plus UBS raising its target price for Gold to $6,200 by the middle of 2026, added to the tailwind that was already pushing the commodity higher. Silver was the big winner Monday, closing up 4.23% at $88.10. Crypto: Cryptocurrency prices fell sharply early on Monday, with Bitcoin dropping 3% to 5% over the co ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is among the 7 Oversold Pharma Stocks to Buy Now. Truist Lowers Neurocrine Biosciences, Inc.'s (NBIX) PT Following 2026 Outlook Update Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the most oversold stocks. TheFly reported on February 17 that Truist reduced its price target on NBIX to $140 from $169 and maintained a Buy rating on the stock. The increase came after management's 2026 projection, and the company's fourth-quarter results were included in the ...

Industry Overview - The pharmaceutical sector in the United States was valued at $634.32 billion in 2024 and is projected to grow to $883.97 billion by 2030, driven primarily by customized medication, which is expected to increase from $169.56 billion in 2024 to $307.04 billion by 2033 at a CAGR of 6.82% [2] - The industry has undergone significant changes due to policy shifts during Donald Trump's administration, including a "Build It Here" campaign to boost domestic manufacturing and a 100% tariff on imported brand-name medications [3] - Regulatory reforms have expedited the approval of generic and biosimilar products, contributing to a larger movement toward cost containment and pharmaceutical self-sufficiency [3] Market Challenges - The pharmaceutical industry faces risks such as the impending $350 billion global patent cliff due to the loss of market exclusivity for key medications like Keytruda and Eliquis [4] - Despite these challenges, growth is expected to be sustained by advancements in gene treatments, biologics, and artificial intelligence [4] - Analysts from Deloitte, PwC, and S&P Global Ratings predict robust credit conditions supported by substantial cash reserves and ongoing industrial innovation [4] Company Highlights - Hims & Hers Health, Inc. (NYSE:HIMS) is identified as one of the most oversold stocks, with a Relative Strength Index (RSI) of 16.68 and a price target upside of 94.39% [9] - The company announced a deal to acquire Eucalyptus for up to $1.15 billion, with plans to finance the agreement through current cash and future U.S. operating cash flows [10][11] - Hims & Hers faced backlash after attempting to launch a $49 oral semaglutide weight-loss pill, leading to a quick reversal of the offering due to regulatory concerns [12] - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is another oversold stock with an RSI of 40.53 and a price target upside of 36.79% [14] - The company reported strong financial results, with Q4 net product sales increasing by 29% year-over-year to $798.3 million and full-year sales reaching $2.83 billion [15] - INGREZZA, one of Neurocrine's products, generated $657.5 million in Q4 sales, reflecting 7% annual growth, supported by strong prescription demand [16]

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences. At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000 ...

Core Insights - Neurocrine Biosciences (NBIX) has successfully demonstrated its business development strategy in 2025, leading to optimism for the company as it enters the first quarter of 2026 [1] Company Performance - The company is positioned in high-growth sectors that are expected to experience exponential expansion [1] - There is a strong focus on disruptive technologies and forward-thinking enterprises, indicating a commitment to innovation [1] Investment Strategy - The approach taken by the company combines fundamental analysis with future trend predictions, aiming to leverage innovation for substantial returns [1]

Core Insights - Neurocrine Biosciences (NBIX) has successfully demonstrated its business development strategy in 2025, leading to optimism for the company as it enters the first quarter of 2026 [1] Company Performance - The company is positioned in high-growth sectors that are expected to experience exponential expansion [1] - There is a strong focus on disruptive technologies and forward-thinking enterprises, indicating a commitment to innovation [1] Investment Strategy - The approach taken by the company combines fundamental analysis with future trend predictions, aiming to leverage innovation for substantial returns [1]

Neurocrine Biosciences Inc (NASDAQ:NBIX) on Wednesday reported fourth-quarter adjusted earnings of $1.88 per share, missing the consensus of $1.89.Sales reached $805.5 million, beating the consensus of $792.47 million.Fourth-quarter net product sales were $798.3 million, up 29% year over year.Ingrezza (drug for involuntary movements) fourth-quarter and full-year 2025 net product sales were $657.5 million and $2.51 billion, reflecting 7% and 9% growth year-over-year, respectively.Results reflected double-dig ...

Core Viewpoint - Neurocrine Biosciences (NBIX) is effectively executing its sales and clinical development strategies, which is expected to build long-term value for shareholders, although this approach may not generate significant market excitement in the short term [1] Group 1: Company Performance - Neurocrine Biosciences is focused on steady execution in sales and clinical development, which is a positive indicator for shareholder value creation [1] Group 2: Market Sentiment - The company's approach, while beneficial for long-term value, tends to be perceived as boring from a market sentiment perspective [1]

Steady execution on sales and clinical development builds value over time for biotechs but tends to be rather boring from a market sentiment standpoint. Neurocrine Biosciences ( NBIX ) is doing the right things to build value for its shareholders, but 2026Analyst’s Disclosure: I/we have a beneficial long position in the shares of NBIX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other tha ...

Core Insights - Neurocrine Biosciences reported $805.5 million in revenue for Q4 2025, marking a year-over-year increase of 28.3% and exceeding the Zacks Consensus Estimate by 2.89% [1] - The company's EPS for the same quarter was $1.88, which is a significant increase from $1.00 a year ago, although it fell short of the consensus estimate of $2.25 by 16.55% [1] Revenue Breakdown - Product sales from INGREZZA reached $657.5 million, slightly below the average estimate of $661.61 million, but still reflecting a year-over-year growth of 6.9% [4] - Total product sales amounted to $798.3 million, surpassing the estimated $788.24 million, with a year-over-year increase of 28.5% [4] - CRENESSITY generated $135.4 million in product sales, exceeding the average estimate of $120.56 million [4] - Collaboration revenue was reported at $7.2 million, above the average estimate of $6.46 million, representing a year-over-year increase of 10.8% [4] - Other product sales were $5.4 million, which is higher than the average estimate of $4.1 million, but this reflects a year-over-year decline of 11.5% [4] Stock Performance - Neurocrine's shares have returned +4.1% over the past month, contrasting with a -0.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]